Everolimus-Induced Pneumonitis in Patients with Neuroendocrine Neoplasms: Real-World Study on Risk Factors and Outcomes.
Rodrigo Gomes TaboadaRachel P RiechelmannCarine MauroMilton BarrosRichard A HubnerMairéad G McNamaraAngela LamarcaJuan W VallePublished in: The oncologist (2022)
Everolimus-induced pneumonitis in the real-world clinical setting is present in one quarter of patients with NENs receiving everolimus and often occurs early. While risk factors for EiP were not identified, patients with EiP had improved survival.